gefitinib tuteur 250 mg comprimido recubierto
tuteur - comprimido recubierto - gefitinib 250 mg comprimido
iressa
astrazeneca uk limited, cheshire, reino unido. - (gefitinib) - comprimido recubierto - 250 mg
iressa®
nipro pharma corporation. - gefitinib - comprimido recubierto - 250 mg
iressa 250 mg comprimidos recubiertos
astrazeneca venezuela, s.a. - gefitinib - comprimido recubierto - 250 mg (a4)
gefitinib seven pharma 250 mg comprimido recubierto
seven pharma guatemala - comprimido recubierto - 250 mg
gefitinib getwell 250 mg comprimidos recubiertos
getwell pharmaceuticals - comprimido recubierto - 250 mg
gefitinib vmg 250 mg tableta recubierta simple tabletas
vmg healthcare products - tabletas - 250 mg
iressa comprimidos recubiertos 250 mg
astrazeneca s.a. - gefitinib - sin formulas
gefitinib neoethicals 250 mg tabletas reubiertas
neoethicals - tabletas recubiertas - 250 mg
lorviqua
pfizer europe ma eeig - lorlatinib - carcinoma, pulmón no microcítico - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.